ReviewTherapeutic advances in hematology2023
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.
Review in Therapeutic advances in hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Application and challenges of chimeric antigen receptor T cell therapy in the treatment of acute myeloid leukemia (Review).Oncology letters · 2026Review
- Novel treatment strategies in acute myeloid leukemia.Blood research · 2026Review
- The diagnostic potential of nanobodies in acute myeloid leukemia.Molecular biology reports · 2026Review
- Integrated scFv identification and CAR T cell generation for AML targeting in vivo.International journal of cancer · 2026Article
- The role of antibody-drug conjugates in the treatment of lung cancer.Frontiers in oncology · 2026Review
- Monoclonal Antibodies as a Breakthrough in Personalised Leukaemia Therapy: What Pharmacists and Doctors Should Know.Pharmacy (Basel, Switzerland) · 2025Review
- Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis.Leukemia · 2025Article
- Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.Journal of hematology & oncology · 2025Review
- Review
- A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Antibody drug conjugates in the clinic.Bioengineering & translational medicine · 2024Review
- Review
- Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia.Biomacromolecules · 2024Article
- Review
- Review
- Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.Blood cancer discovery · 2024Review
- Article
- Recent advances in CAR-T cell therapy for acute myeloid leukaemia.Journal of cellular and molecular medicine · 2024Review
- Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.Cancer reports (Hoboken, N.J.) · 2024Article
- Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gemtuzumab-ozogamicin (GO) is an antibody-drug conjugate (ADC) in which a monoclonal antibody targeting CD33 is covalently linked to the toxin calicheamicin. GO was initially approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with CD33
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.